Topical Erythropoietin for Treatment of Scleral Necrosis.
Ocul Immunol Inflamm
; 30(7-8): 1701-1706, 2022.
Article
em En
| MEDLINE
| ID: mdl-34124987
ABSTRACT
PURPOSE:
To investigate the safety and efficacy of topical erythropoietin for the treatment of scleral necrosis.METHODS:
This study enrolled eight consecutive patients with scleral necrosis due to previous ocular surgery, rheumatoid arthritis-associated necrotizing anterior scleritis, and thermal and chemical burns. Conventional treatments failed to heal avascular scleral lesions in all eyes. Patients were treated with topical erythropoietin (3000 IU/mL) four times a day.RESULTS:
The mean patient age was 37.6 ± 15.5 years. The interval between the development of scleral necrosis and initiation of topical erythropoietin was 25.6 ± 12.0 days. The necrotic sclera completely healed within 31.9 ± 16.9 days in all patients. The avascular lesions did not recur, and there was no evidence of side effects during the study.CONCLUSION:
Our results showed that topical erythropoietin could be safely used to manage scleral necrosis. Randomized clinical trials are needed to further explore the efficacy of this intervention in patients with avascular scleral lesions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclera
/
Necrose
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article